Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy - a prospective randomised controlled trial

Abstract

BackgroundIn 2010 the ‘Polymedication Check’ (PMC), a pharmacist-led medication review, was newly introduced to be delivered independently from the prescriber and reimbursed by the Swiss health insurances. This study aimed at evaluating the impact of this new cognitive service focusing on medicines use and patients’ adherence in everyday life.MethodsThis randomised controlled trial was conducted in 54 Swiss community pharmacies. Eligible patients used ≥4 prescribed medicines over >3 months. The intervention group received a PMC at study start (T-0) and after 28 weeks (T-28) while the control group received only a PMC at T-28.Primary outcome measure was change in patients’ objective adherence, calculated as Medication Possession Ratio (MPR) and Daily Polypharmacy Possession Ratio (DPPR), using refill data from the pharmacies and patient information of dosing.Subjective adherence was assessed as secondary outcome by self-report questionnaires (at T-0 and T-28) and telephone interviews (at T-2 and T-16), where participants estimated their overall adherence on a scale from 0–100 %.Results and discussionA total of 450 patients were randomly allocated to intervention (N = 218, 48.4 %) and control group (N = 232, 51.6 %). Dropout rate was fairly low and comparable for both groups (NInt = 37 (17.0 %), NCont = 41 (17.7 %), p = 0.845). Main addressed drug-related problem (DRP) during PMC at T-0 was insufficient adherence to at least one medicine (N = 69, 26.7 %). At T-28, 1020 chronic therapies fulfilled inclusion criteria for MPR calculation, representing 293 of 372 patients (78.8 %). Mean MPR and adherence to polypharmacy (DPPR) for both groups were equally high (MPRInt = 88.3, SD = 19.03; MPRCont = 87.5, SD = 20.75 (p = 0.811) and DPPRInt = 88.0, SD = 13.31; DPPRCont = 87.5, SD = 20.75 (p = 0.906), respectively).Mean absolute change of subjective adherence between T-0 and T-2 was +1.03 % in the intervention and −0.41 % in the control group (p = 0.058). The number of patients reporting a change of their adherence of more than ±5 points on a scale 0–100 % between T-0 and T-2 was significantly higher in the intervention group (NImprovement = 30; NWorsening = 14) than in the control group (NImprovement = 20; NWorsening = 24; p = 0.028).ConclusionThrough the PMC pharmacist were able to identify a significant number of DRPs. Participants showed high baseline objective adherence of 87.5 %, providing little potential for improvement. Hence, no significant increase of objective adherence was observed. However, regarding changes in subjective adherence of more than ±5 % the PMC showed a positive effect.Trial registrationClinical trial registry database, NCT01739816; first entry on November 27, 2012.Electronic supplementary materialThe online version of this article (doi:10.1186/s12913-016-1384-8) contains supplementary material, which is available to authorized users.

Organização dos serviços farmacêuticos no Sistema Único de Saúde em regiões de saúde

“…Evidence has demonstrated the impact of clinical services for the community 18,19 . The purpose of pharmacotherapeutic monitoring/follow-up of users, and pharmacotherapeutic review, is evaluation of the medical drugs used by patients, prescribed and not prescribed, for the purpose of identifying drug interactions, or low levels of adherence to treatment, such as might be compromising the therapeutic results.…”

Value of a Community‐Based Medication Management Review Service in Jordan: A Prospective Randomized Controlled Study

“…The financial burden and detrimental clinical outcomes associated with these problems still needs resolution . Hence addressing this issue by establishing effective pharmaceutical care services in community pharmacies is vital …”

Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy

“…Previous research has demonstrated the impact of community pharmacists in educating about and managing medications in patients who require polypharmacy [54], but studies have not been completed yet in the muscular dystrophy population. Such studies are needed.…”